€39.44 -0.7 -1.7%
Last Trade - 18/09/20
| Market Cap | £19.95bn |
| Enterprise Value | £51.28bn |
| Revenue | £33.19bn |
| Position in Universe | 53rd / 1040 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 23,459 | 27,995 | 29,471 | 33,886 | 33,530 | 35,409 | 36,866 | 38,818 | +8.6% | ||
| +2.6 | +30.5 | +13.8 | +20.1 | -25.4 | +34.0 | -7.80 | +12.5 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes in intravenously administered generic drugs (IV drugs), clinical nutrition and infusion therapies. It also supplies hospitals with medical devices and products of transfusion technology. Fresenius Helios is a private hospital operator, with over 130 facilities in Germany, including maximum care hospitals and rehabilitation centers and, through Quironsalud, over 80 hospitals and outpatient centers, as well as approximately 300 Occupational Risk Prevention Centers in Spain. Fresenius Vamed manages projects and provides services for health care facilities worldwide, from development and turnkey construction to maintenance and total operational management.
| Last Annual | December 31st, 2019 |
| Last Interim | June 30th, 2020 |
| Incorporated | January 28, 2011 |
| Public Since | December 18, 1986 |
| No. of Shareholders: | n/a |
| No. of Employees: | 302,846 |
| Sector | Healthcare |
| Industry | Healthcare Providers & Services |
| Index | FTSEurofirst 300 Health Care Equipment & Services , FTSEurofirst 100 , FTSEurofirst 300 , FTSEurofirst 300 Eurozone , FTSEurofirst 300 Ex UK, Xetra DAX , Xetra Prime All Share , |
| Exchange | XETRA |
| Shares in Issue | 551,766,311 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Else-Kroener-Str 1, BAD HOMBURG VOR DER HOHE, 61352, Germany |
| Web | https://www.fresenius.de/ |
| Phone | +49 6172 6080 |
| Contact | Markus Georgi (Senior Vice President Investor Relations and Sustainability) |
| Auditors | KPMG AG Wirtschaftsprufungsgesellschaft |
As of 18/09/20, shares in Fresenius SE & Co KGaA are trading at €39.44, giving the company a market capitalisation of £19.95bn. This share price information is delayed by 15 minutes.
Shares in Fresenius SE & Co KGaA are currently trading at €39.44 and the price has moved by -12.96% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Fresenius SE & Co KGaA price has moved by -6.56% over the past year.
Of the analysts with advisory recommendations for Fresenius SE & Co KGaA, there are there are currently 9 "buy" , 4 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Fresenius SE & Co KGaA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Fresenius SE & Co KGaA is scheduled to issue upcoming financial results on the following dates:
The Fresenius SE & Co KGaA dividend yield is 2.13% based on the trailing twelve month period.
Last year, Fresenius SE & Co KGaA paid a total dividend of 0.84, and it currently has a trailing dividend yield of 2.13%. Looking ahead, Fresenius SE & Co KGaA has not announced an ex-dividend date yet.
Fresenius SE & Co KGaA has yet to annouce their ex-dividend date. The historic dividend yield on Fresenius SE & Co KGaA shares is currently 2.13%.
To buy shares in Fresenius SE & Co KGaA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Fresenius SE & Co KGaA are currently trading at €39.44, giving the company a market capitalisation of £19.95bn.
Here are the trading details for Fresenius SE & Co KGaA:
Based on an overall assessment of its quality, value and momentum, Fresenius SE & Co KGaA is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Fresenius SE & Co KGaA are currently priced at €39.44. At that level they are trading at 33.87% discount to the analyst consensus target price of 0.00.
Analysts covering Fresenius SE & Co KGaA currently have a consensus Earnings Per Share (EPS) forecast of 3.276 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fresenius SE & Co KGaA. Over the past six months, the relative strength of its shares against the market has been 6.44%. At the current price of €39.44, shares in Fresenius SE & Co KGaA are trading at -7.51% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Fresenius SE & Co KGaA PE ratio based on its reported earnings over the past 12 months is 11.68. The shares are currently trading at €39.44.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Fresenius SE & Co KGaA's management team is headed by:
Here are the top five shareholders of Fresenius SE & Co KGaA based on the size of their shareholding:
